B.Riley reiterates Buy on Viking Therapeutics stock after trial data
B.Riley reiterated a Buy rating and $85 price target on Viking Therapeutics (VKTX) after positive Phase 1 trial data for its weight loss drug VK2735. The stock trades at $37.45, with a Strong Buy consensus. Trial results showed significant weight loss in patients, with 98% achieving at least 5% weight loss. The company reported narrower-than-expected Q2 losses, and Oppenheimer maintains an Outperform rating with a $100 target.
How this was made
The 30-second read
Why it matters
Positive data could trigger price appreciation and increased coverage.
Market read
First disclosure of promising Phase 1 data for VKTX, likely to move the stock.
What to watch
Adverse event rates comparable to placebo; regulatory timeline uncertain.
Background
Article summarizes recent VKTX trial data and analyst upgrades.
Ticker impact
Phase 1 subcutaneous VK2735-102 maintenance trial data released, showing 21.7% weight loss vs 0.3% placebo.
Potential upside of 15-20% if data leads to further clinical advancement.
First report of significant weight‑loss efficacy; analysts have raised earnings forecasts.
Market effects
Strengthens outlook for obesity‑treatment biotech sector.
Positive for US biotech investors.
May influence global obesity‑drug pipeline expectations.
Counterpoint
Trial size is small; efficacy may not translate to later phases.
Key entities
- companyViking Therapeutics
Biotech developing GLP‑1/GIP obesity treatments.
